Jun 2026 (Q2 FY26) — Aug 10, 2026
Fractyl Health Q2 FY26 — Revita Shows Durable Weight Maintenance Post-GLP-1, Pivotal Data Expected Early Q4
Read the full callFractyl Health (GUTS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Fractyl Health earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -25.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.38 −10.97% · −$0.17
Performance +7.0% 1Y
1Y: $1.29 on 17 Oct 2025 → $1.38. High $6.53 (30 Sept 2026), low $0.39 (17 Feb 2026).
- Previous close
- $1.55
- 52-week range
- $0.39 – $6.53
- One year
- −0.72%
Overview
- Symbol
- GUTS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Fractyl Health earnings calls (GUTS)
Financials
What the filings say
Net profit, year on year: +8% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | — | — | — | — | — | — |
| Operating profit | -24 | -25 | -25 | -26 | -23 | -23 | -21 | -19 |
| Operating margin | −169957.1% | −840333.3% | — | — | — | — | — | — |
| Other income | 1 | 0 | 1 | -2 | -23 | -20 | 30 | -6 |
| Net profit | -23 | -25 | -24 | -28 | -46 | -44 | 9 | -26 |
| EPS ($ per share) | -0.48 | — | -0.49 | -0.57 | -0.71 | — | 0.06 | -0.16 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | 0 | 0 | 0 |
| Reserves | -347 | -415 | -556 |
| Total liabilities | 114 | 80 | 112 |
| Fixed assets | 0 | 3 | 2 |
| Total assets | 76 | 108 | 121 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -43 | -66 | -90 |
| Cash from investing | -0 | -2 | -1 |
| Cash from financing | 27 | 101 | 105 |
| Net cash flow | -16 | 34 | 14 |
| Capital expenditure | -0 | -2 | -1 |
| Free cash flow | -43 | -67 | -91 |
Insider filings
7 filings between Dec 4, 2025 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
$187.3K
7 purchases by 5 insiders
Sales
None
No insider sold shares.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| BRADLEY WILLIAM | $90.2K | — | Sep 14, 2026 |
| Rajagopalan Harith | $38.3K | — | Jun 10, 2026 |
| Sheffield Ian | $25.5K | — | Jun 10, 2026 |
| Royan Ajay | $19.6K | — | Jun 12, 2026 |
| Smith Weber Lara | $13.7K | — | Jun 8, 2026 |
Latest filings (26)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | BRADLEY WILLIAM Director | Purchase | 64,516 | $39.9K |
| Jun 12, 2026 | Royan Ajay Director | Purchase | 23,000 | $19.6K |
| Jun 10, 2026 | Sheffield Ian Director | Purchase | 35,000 | $25.5K |
| Jun 10, 2026 | BRADLEY WILLIAM Director | Purchase | 68,493 | $50.3K |
| Jun 10, 2026 | Rajagopalan Harith Chief Executive Officer | Purchase | 25,000 | $18.3K |
| Jun 8, 2026 | Smith Weber Lara Chief Financial Officer | Purchase | 20,000 | $13.7K |
| Dec 4, 2025 | Rajagopalan Harith Chief Executive Officer | Purchase | 10,416 | $20.0K |
| Mar 14, 2025 | Royan Ajay Director | Purchase | 17,901 | $23.0K |
| Mar 14, 2025 | Barnes Kelly Ann Director | Purchase | 31,000 | $40.2K |
| Mar 13, 2025 | BRADLEY WILLIAM Director | Purchase | 16,129 | $20.4K |
| Mar 13, 2025 | SCHULMAN AMY W Director | Purchase | 8,550 | $10.0K |
| Mar 13, 2025 | Conaway Samuel Director | Purchase | 8,550 | $10.0K |
| Jan 31, 2025 | Caplan Jay David President, Chief Product Off. | Sale 10b5-1 plan | 22,346 | $40.5K |
| Jan 31, 2025 | Rajagopalan Harith Chief Executive Officer | Option exercise 10b5-1 plan | 90,972 | $154.7K |
| Jan 31, 2025 | Rajagopalan Harith Chief Executive Officer | Sale 10b5-1 plan | 90,972 | $165.2K |
| Jan 31, 2025 | Caplan Jay David President, Chief Product Off. | Option exercise 10b5-1 plan | 22,346 | $38.0K |
| Jan 30, 2025 | Caplan Jay David President, Chief Product Off. | Sale 10b5-1 plan | 21,472 | $41.8K |
| Jan 30, 2025 | Rajagopalan Harith Chief Executive Officer | Option exercise 10b5-1 plan | 20,948 | $35.6K |
| Jan 30, 2025 | Rajagopalan Harith Chief Executive Officer | Sale 10b5-1 plan | 20,948 | $40.8K |
| Jan 30, 2025 | Caplan Jay David President, Chief Product Off. | Option exercise 10b5-1 plan | 21,472 | $36.5K |
| Nov 11, 2024 | Caplan Jay David President, Chief Product Off. | Sale | 64,197 | $158.5K |
| Nov 11, 2024 | Rajagopalan Harith Chief Executive Officer | Sale | 96,517 | $238.4K |
| Nov 10, 2024 | Rajagopalan Harith Chief Executive Officer | Option exercise | 216,924 | $0 |
| Nov 10, 2024 | Caplan Jay David President, Chief Product Off. | Option exercise | 187,257 | $0 |
| Sep 12, 2024 | Caplan Jay David President, Chief Product Off. | Option exercise | 95,484 | $162.3K |
| Sep 12, 2024 | Caplan Jay David President, Chief Product Off. | Sale | 65,000 | $188.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for FRACTYL HEALTH, INC.
Free account. Everything above stays public.
Write why you follow FRACTYL HEALTH, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading